Sarah Butler Purchases 22,617 Shares of Australian Clinical Labs (ASX:ACL) Stock

Australian Clinical Labs Limited (ASX:ACL) insider Sarah Butler purchased 22,617 shares of the stock in a transaction dated Thursday, February 19th. The shares were acquired at an average cost of A$2.21 per share, for a total transaction of A$49,983.57.

Australian Clinical Labs Price Performance

The company has a quick ratio of 0.53, a current ratio of 0.64 and a debt-to-equity ratio of 174.00. The company has a market capitalization of $728.27 million, a P/E ratio of 30.38, a price-to-earnings-growth ratio of -0.36 and a beta of 1.18.

Australian Clinical Labs Dividend Announcement

The firm also recently announced a Interim dividend, which will be paid on Monday, March 30th. Stockholders of record on Monday, March 30th will be given a $0.037 dividend. This represents a dividend yield of 170.0%. The ex-dividend date of this dividend is Wednesday, March 11th. Australian Clinical Labs’s dividend payout ratio (DPR) is 150.00%.

Australian Clinical Labs Company Profile

Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services.